Exelixis Inc. Stock
€38.84
Your prediction
Financial data and news for Exelixis
sharewise wants to provide you with the best news and tools for Exelixis, so we directly link to the best financial data sources.
Financials
News
Exelixis Stock: Executives Sell as Shares Near Peak
Exelixis is experiencing significant insider selling activity while its stock trades near its 52-week high of €37.64. Three high-ranking executives recently reduced their holdings in substantial
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45
2 Top Stocks to Buy With Less Than $100
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that
Why Exelixis Stock Is Skyrocketing Today
Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening.
Why Exelixis Stock Trounced the Market on Thursday
Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q4 2024 Earnings CallFeb 11, 2025, 5:00 p.m. ET
Operator
Source Fool.com
Exelixis Posts 63.7% Profit Surge
Exelixis (NASDAQ:EXEL), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and